Brief: Athenex Announces Exclusive License Agreement With National Cancer Institute To Utilize T Cell Receptors Targeting Mutated P53, Kras, And Egfr For The Development Of Autologous And Allogeneic Cell Therapies

Athenex

09/11/2021 13:43

Nov 9 (Reuters) - Athenex Inc  ATNX.O :
    * ATHENEX ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH
NATIONAL
CANCER INSTITUTE TO UTILIZE T CELL RECEPTORS TARGETING MUTATED
P53, KRAS, AND EGFR FOR THE DEVELOPMENT OF AUTOLOGOUS AND
ALLOGENEIC CELL THERAPIES

Source text for Eikon:  ID:nGNXbcV7LH 
Further company coverage:  ATNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))